Blue Hat Announces an Updated Effective Time for 1-for-50 Reverse Stock Split

(NASDAQ:BHAT), XIAMEN, China, March 04, 2026 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT), a Cayman Islands exempted company, previously reported on March 3, 2026 that it expects to implement a 1-for-50 reverse stock split on its ordinary shares (the “Reverse Stock Split”) effective Friday, March 6, 2026, […]

Conifex Announces Secured Term Loan with BDC under the Softwood Lumber Guarantee Program

(TSX:CFF), VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex“) (TSX: CFF) announced today that its wholly-owned subsidiary Conifex Mackenzie Forest Products Inc., has completed a $19 million secured term loan with the Business Development Bank of Canada (“BDC“) under the Softwood Lumber Guarantee Program. The loan has a maturity date

Blue Hat Announces an Updated Effective Time for 1-for-50 Reverse Stock Split

Blue Hat Announces an Updated Effective Time for 1-for-50 Reverse Stock Split GlobeNewswire March 05, 2026 XIAMEN, China, March 04, 2026 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT), a Cayman Islands exempted company, previously reported on March 3, 2026 that it expects to implement a 1-for-50 reverse

Conifex Announces Secured Term Loan with BDC under the Softwood Lumber Guarantee Program

Conifex Announces Secured Term Loan with BDC under the Softwood Lumber Guarantee Program GlobeNewswire March 05, 2026 VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex“) (TSX: CFF) announced today that its wholly-owned subsidiary Conifex Mackenzie Forest Products Inc., has completed a $19 million secured term loan with the Business Development

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Navan, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NAVN

(NASDAQ:NAVN), NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Navan, Inc. (NASDAQ: NAVN) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Offering Documents”) issued in connection with Navan's October

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Navan, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NAVN

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Navan, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NAVN GlobeNewswire March 05, 2026 NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of

Bragar Eagel & Squire, P.C. Urges Bath & Body Works, Inc. (NYSE: BBWI) Stockholders with Significant Losses to Contact the Firm

(NYSE:BBWI), Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Bath & Body Works (BBWI) To Contact Him Directly To Discuss Their Options If you purchased or acquired Bath & Body Works securities between June 4, 2024 and November 19, 2025 and would like to discuss your legal rights,

Bragar Eagel & Squire, P.C. Urges Bath & Body Works, Inc. (NYSE: BBWI) Stockholders with Significant Losses to Contact the Firm

Bragar Eagel & Squire, P.C. Urges Bath & Body Works, Inc. (NYSE: BBWI) Stockholders with Significant Losses to Contact the Firm GlobeNewswire March 05, 2026 Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Bath & Body Works (BBWI) To Contact Him Directly To Discuss Their Options If you

Cardio Slim Tea Homocysteine Claims Evaluated in 2026 Consumer Report on Blood Pressure Support, Ingredient Transparency, and Weight Management Marketing Trends

Cardio Slim Tea Homocysteine Claims Evaluated in 2026 Consumer Report on Blood Pressure Support, Ingredient Transparency, and Weight Management Marketing Trends Informational 2026 analysis examines Cardio Slim Tea ingredients, homocysteine positioning, blood pressure normalization claims, pricing disclosures, and what publicly available research indicates GlobeNewswire March 04, 2026 Aurora, CO, March 04, 2026 (GLOBE NEWSWIRE) —

PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026

— If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription

Scroll to Top